4-Nitroaniline

4-Nitroaniline

SCHEMBL3397241

CC(C)[C@H](N)C(=O)O.C[C@H](N)C(=O)O.C[C@H](N)C(=O)O.Nc1ccc([N+](=O)[O-])cc1.O=C(O)[C@@H]1CCCN1

nearest known ligand 0.39

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

SLC5A2

The experimentally established mechanism targets of 4-Nitroaniline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A3 Q01959 2/20 0.39
ALDH1A1 P00352 2/20 0.38
SLC1A3 P43003 1/20 0.36
SLC1A2 P43004 1/20 0.36
SLC1A1 P43005 1/20 0.36
ESR1 P03372 2/20 0.35
CYP19A1 P11511 2/20 0.35
ESR2 Q92731 2/20 0.35
KMT2A Q03164 3/20 0.34
PKM P14618 1/20 0.34
EPHX1 P07099 1/20 0.34
MEN1 O00255 2/20 0.33
MAPT P10636 2/20 0.33
GAA P10253 3/20 0.33
MMP1 P03956 1/20 0.33
MMP2 P08253 1/20 0.33
MMP3 P08254 1/20 0.33
MMP7 P09237 1/20 0.33
MMP9 P14780 1/20 0.33
MMP13 P45452 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
4-Nitroaniline SCHEMBL6600220 0.95 ALDH1A1 (0.42) SLC6A3ALDH1A1SLC1A3SLC1A2SLC1A1
4-Nitroaniline SCHEMBL16269538 0.93 SLC6A3 (0.40) SLC6A3ALDH1A1SLC1A3SLC1A2SLC1A1
4-Nitroaniline SCHEMBL3413641 0.87 ALDH1A1 (0.50) SLC6A3ALDH1A1ESR1CYP19A1ESR2
Phenylalanine SCHEMBL3431329 0.84 DPP4 (0.41) SLC6A3KMT2APKMMEN1MAPT
Phenylalanine SCHEMBL8981660 0.84 DPP4 (0.41) SLC6A3KMT2APKMMEN1MAPT
Valine SCHEMBL2113294 0.82 SLC7A5 (0.47) ALDH1A1KMT2AMEN1DPP4DPP8
Valine SCHEMBL8740685 0.82 SLC7A5 (0.47) ALDH1A1KMT2AMEN1DPP4DPP8
Valine SCHEMBL28486680 0.82 SLC7A5 (0.47) ALDH1A1KMT2AMEN1DPP4DPP8
4-Nitroaniline SCHEMBL5768376 0.81 ALDH1A1 (0.44) SLC6A3ALDH1A1ESR1CYP19A1ESR2
4-Nitroaniline SCHEMBL29058965 0.80 ALDH1A1 (0.58) ALDH1A1SLC1A3SLC1A2SLC1A1ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1269990-B1 Cosmetic or dermatological composition comprising acylaminoamide derivatives OREAL (FR) 2010-10-13 EP disclosed
EP-1269988-B1 Cosmetic or dermatological composition comprising acylaminoamide derivatives OREAL (FR) 2007-12-05 EP disclosed
EP-1275372-B1 Cosmetic or dermatological composition comprising a N-acylaminoamide derivative and a metalloproteinase inhibitor OREAL (FR) 2007-06-13 EP disclosed
EP-1399113-B1 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING N-ACYLAMINOAMIDE DERIVATIVES OREAL (FR) 2007-03-21 EP disclosed
EP-1292608-B1 NOVEL COMPOUNDS OF THE N-ACYLAMINO-AMIDE FAMILY, COMPOSITIONS COMPRISING SAME, AND USES OREAL (FR) 2004-07-21 EP disclosed
EP-1292608-A2 NOVEL COMPOUNDS OF THE N-ACYLAMINO-AMIDE FAMILY, COMPOSITIONS COMPRISING SAME, AND USES L'OREAL (FR) 2003-03-19 EP disclosed
US-20030044438-A1 Cosmetic or dermatological composition comprising an association between a compound of the N-acylaminoamide family and at least one matrix metalloproteinase inhibitor L'OREAL (FR) 2003-03-06 US disclosed
EP-1275372-A1 Cosmetic or dermatological composition comprising a N-acylaminoamide derivative and a metalloproteinase inhibitor L'OREAL, S.A. (FR) 2003-01-15 EP disclosed
EP-1269989-A1 Cosmetic or dermatological composition comprising acylaminoamide derivatives L'OREAL (FR) 2003-01-02 EP disclosed
EP-1269988-A1 Cosmetic or dermatological composition comprising acylaminoamide derivatives L'OREAL (FR) 2003-01-02 EP disclosed
EP-1269990-A1 Cosmetic or dermatological composition comprising acylaminoamide derivatives L'OREAL (FR) 2003-01-02 EP disclosed
WO-2001094381-A2 NOVEL COMPOUNDS OF THE N-ACYLAMINO-AMIDE FAMILY, COMPOSITIONS COMPRISING SAME, AND USES L'OREAL (FR) 2001-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030044438-A1 Cosmetic or dermatological composition comprising an association between a compound of the N-acylaminoamide family and at least one matrix metalloproteinase inhibitor SERPINB1, ELANE, MMP7 SLC6A3 4728/4885ALDH1A1 573/4885SLC1A3 4141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.